JD Mowery, new KBI Biopharma and Selexis SA CEO
April 20, 2023 11:38 AM EDTUpdated April 21, 09:16 AM
People
Pharma
Manufacturing

KBI Bio­phar­ma and Se­lex­is hire J.D. Mow­ery as new CEO

Tyler Patchen

News Reporter

KBI Bio­phar­ma is the lat­est con­tract man­u­fac­tur­er mak­ing change at the top in an on­go­ing C-suite shuf­fle oc­cur­ring across the CD­MO space over the past …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

A service from the Financial Times